Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is an interventional, randomized open-label, parallel-group, multicenter, dose
escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd
line treatment in mCRC patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
China Medical University, China
Collaborators:
Liaoning Tumor Hospital & Institute The First People's Hospital of Jingzhou